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Alzheimer’s disease (AD) is the most common form of old age dementia, and mild cognitive impairment (MCI) often precedes
AD. In our previous study (Julkunen et al. 2008), we found that the combination of transcranialmagnetic stimulation (TMS) and
electroencephalography (EEG) was able to ﬁnd distinct diﬀerences in AD and MCI patients as compared to controls. Here, we
reanalyzed the small sample data from our previous study with the aim to test the sensitivity of the TMS-EEG characteristics to
discriminatecontrolsubjects (n = 4)fromMCI(n = 5)andAD(n = 5)subjects. Furthermore, weinvestigated howtheTMS-EEG
response characteristics related to the scores of the dementia rating scales used to evaluate the severity of cognitive decline in these
subjects. We found that the TMS-EEG response P30 amplitude correlated with cognitive decline and showed good speciﬁcity and
sensitivity in identifying healthy subjects from those with MCI or AD. Given the small sample size, further studies may be needed
to conﬁrm the results.
1.Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
which leads to dementia through a progressive cognitive
decline. In Europe, AD aﬀects over 5% of population aged
above 70 years [1]. This makes it the most common cause of
dementia in old age. It has been postulated that the impair-
ment of the lateral cholinergic pathway originating from the
Meynert’s nucleus would characterize AD and contributes
to its typical symptom of memory loss [2, 3]. AD-related
pathology leads to the degeneration of the large cortical
pyramidal neurons [4], and subsequently impairment of
functional connectivity takes place [5]. Before the diagnosis
ofADcanbeset,subjectsoftensuﬀerfromimpaired episodic
memory [6]. The stage characterised by mild memory or
other cognitive loss is called mild cognitive impairment
(MCI), and it has been proposed as a prodromal state of AD.
Thus, subjects with MCI have an increased risk to develop
AD [7–9]. Understanding the pathophysiology of MCI
would be essential for predicting and possibly in the future
preventing the development of AD. It is possible that altered
functional connectivity precedes structural changes, and
therefore, a sensitive method to detect those early functional
changes would be useful in the diagnostics of MCI and AD.
Early identiﬁcationofADwouldbedesirable,asitcouldhelp
aiming the current treatment to the appropriate subjects.
With the prospects of obtaining treatments that modify the
course of AD, accurate identiﬁcation of subjects who will
develop AD is essential.
E a r l i e ri th a sb e e ns h o w nt h a tt h ep r i m a r ym o t o rc o r t e x
experiences changes during the development of AD, which
also relate to the severity of the disease [10]. Structural2 International Journal of Alzheimer’s Disease
changes in M1 are mild and appear late as compared to
other brain areas, and therefore, motor function also appears
intact in early AD [11–14]. Several earlier TMS studies
have found that AD patients have reduced resting motor
threshold (MT) of the primary motor cortex [3, 15–21].
Alagona et al. reported that the resting MT correlates
inversely with the disease severity [15]. This implies that
the inhibitory control is reduced in AD, which is also
supported by reported shortening of cortical silent period
[21]. Additionally, previous studies have reported reduction
in short-latency aﬀerent inhibition (SAI) in AD [18, 22–24].
SAI has been considered as a marker of central cholinergic
activity [25] and is likely of cortical origin [26, 27]. Hence,
motor cortex functions, especially intracortical inhibition,
suﬀer during the development of AD. Earlier, Sakuma et al.
[23] showed that SAIis not impaired in MCI,suggesting that
the cholinergic activity shown to be impaired in AD may still
be normal in MCI. Several studies have been conducted to
solve this question and supporting as well as contradicting
results have been published [28–31]. Hence, the cholinergic
changesrelated toMCIshouldbe interpretedcarefully, asthe
cholinergic regulation in MCI is still unclear. Furthermore,
in AD, there is a tendency towards a reduced short-latency
intracortical inhibition (SICI), a diﬀerent form of inhibition
evoked by using paired-pulse TMS [3, 18, 19]. SICI has been
connected with intracortical GABAA activity [32].
Combining TMS with electroencephalography (EEG)
oﬀersadirect noninvasive method tostudycorticalreactivity
and connectivity in physiological and pathological condi-
tions [33–38]. Previously, we have shown that TMS-EEG can
reveal abnormalities in functional cortical connectivity and
reactivity in the AD subjects [39]. Our main ﬁnding was that
the P30 response of TMS-EEG was signiﬁcantly reduced in
ADas comparedtocontrols and MCI,andthatthereduction
was localized to the ipsilateral temporoparietal area as well
as contralateral frontocentral area, that is, sensorimotor
area, connected to M1. In the past, TMS-EEG response,
when focused on M1, has been shown to exhibit several
distinguishable peaks: N15, P30, N40, P60, and N100 [33,
35, 36, 38, 40–43]. Prior studies have related the early peaks
N15 and P30 to the M1 activation. P30 has been suggested to
reﬂect activity around the premotor cortex on the stimulated
side, and it has been reported that P30 may increase due
to long-term potentiation induced by repetitive TMS [41].
Furthermore, P30 has been suggested to involve pathways
between subcortical structures such as thalamic nuclei or
basal ganglia and cortex [40]. Also, P30 has been shown
to vanish with nonoptimal orientation of the stimulation
coil in respect to the cortical structures [40]. Therefore, the
use of neuronavigation in combination with TMS allows
controlling of the stimulation direction in respect to the
subject’s brain anatomy and results in optimized motor
responses [44], and likely optimized TMS-EEG responses.
We wanted to investigate subject-speciﬁc diﬀerences in
intracortical connectivitybetweenhealthy subjects, and MCI
or AD patients. We utilized and reanalyzed our previously
published data [39], which indicated that especially the P30
amplitude of the TMS-EEG response could be decreased
in AD. We further evaluated the sensitivity of the P30
amplitude changes in discriminating healthy subjects from
those exhibiting cognitive impairment (MCI and AD). Fur-
thermore, we tested whether P30 amplitude would directly
relate to commonly categorizing scores of dementia rating
scales. On the basis of the ﬁndings of our previous study, we
hypothesizedthatP30amplitudewoulddeclineasthedisease
becomes more severe and correlate with the dementia rating
scales.
2.Materialsand Methods
2.1. Subjects. In the present study, our previously published
data was further analyzed. A small size sample including
four control subjects (age: 78 ± 3 years, 3 females, 1 male),
ﬁve MCI subjects (age: 74 ± 8 years, 2 females, 3 males),
and ﬁve AD subjects (age: 73 ± 8y e a r s ,2f e m a l e s ,3
males) was recruited for the original study. All subjects were
right handed. Each subject gave written informed consent,
and the study was approved by the local ethics committee.
Categorizingofthese subjectstotheirgroupswas donebased
on a standard rating [45] and is explained in more detail
in the original paper [39]. Brieﬂy, the MCI subjects fulﬁlled
the following characteristics [7]: (1) subjective memory
impairment corroborated by an informant, (2) objective
memory impairment, that is, a score of 0.5 in the clinical
dementia rating (CDR) scale [45]w i t ha tl e a s t0 . 5o nt h e
memory subscale and a score of 1.5SD below the average
of a normative age-matched sample group in at least one
memory test, (3) normal global cognitive function (Mini-
Mental-State Examination score (MMSE) of at least 20
[46]), (4) normal activities of daily living, and (5) no
dementia according to the NINCDS-ADRDA criteria [11].
The MCI subjects were classiﬁed as multidomain amnestic
MCI [47]. Diagnosis of AD was made according to the
NINCDS-ADRDA criteria for probable AD [11]. All the
AD patients were on cholinesterase inhibitors, while other
subjects had no medication aﬀecting cognition at the time
of measurements.
2.2. Measurement System and Protocol. Navigated TMS was
used to probe the motor cortex of the subjects (Figure 1),
that is, the primary motor cortex (M1) of the subjects was
mapped for the representation area of the thenar mus-
culature of both hands. The stimulation system consisted
of a Magstim BiStim stimulator (Magstim Ltd., Whit-
land, UK)and a 70mm ﬁgure-of-eight TMScoilwith mono-
phasic pulse form. Stimulation-triggered EEG responses
were recorded with 1450Hz sampling frequency and 16bit
precisionusinga60-channelTMS-compatibleEEGampliﬁer
(Nexstim Ltd., Helsinki, Finland). Navigation of the TMS
system utilized T1-weighted 3D magnetic resonance images
(imaged with Siemens Magnetom Avanto, Siemens, Erlan-
gen, Germany). The navigation was conducted using eXimia
navigation system (version 2.0, Nexstim Ltd., Helsinki,
Finland). Resting state MT at the “hotspot” was deter-
mined using a threshold-hunting protocol [48]. For measur-
ing TMS-induced muscle responses, electromyography was
recorded (ME6000, Mega Electronics Inc., Kuopio, Finland)International Journal of Alzheimer’s Disease 3
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Figure 1: Motor cortex representation area of a control patient.
TMS was focused at the “hotspot” of thenar muscle representation
on the primary motor cortex (M1). The yellow dots present
stimulation locations during the mapping of the hotspot in the
vicinity of M1. The red spots indicate the hotspots, which were
located within normal variation in each group [57].
fromtheopponenspollicismuscleusingpregelleddisposable
Ag-AgCl surface electrodes. TMS-induced EEG responses
were recorded from >50 trials elicited with an interstimulus
interval of 3–5s with a stimulation intensity of 110% of the
determinedMT.Foramorethoroughsystemdescription,the
reader is referred to our previous paper [39]. Both hemi-
spheres were separately investigated, and the stimulation
order of the hemispheres was randomized.
2.3. Analysis of TMS-EEG. The oﬄine analysis of EEG was
performed using Matlab 7.2 (Mathworks Inc., Natick, MA).
Zero padding for 10ms after the TMS pulse was applied
to dampen the TMS-induced artefact. Segmented EEG was
bandpass ﬁltered to 1–50Hz. Any segments contaminated
by blinks, as observed from vertical electro-oculogram, were
removed from the analyses. Also, in some cases, a bad
channel signal due to poor contact was replaced with a signal
linearly interpolated from the neighbouring good channels.
Manual artefact removal was conducted, prior to rereferenc-
ing all electrodes to common average. Baseline correction
for 100ms before each stimulus was conducted prior to
averaging the segments. Averaged TMS-EEG responses over
all trials were used in the statistical comparisons (Figure 2).
Our interest was in the P30 response, earlier shown to be
inﬂuenced by AD [39]. Analysis of the P30 responses was
conducted from an electrode close to the site of stimu-
lationbasedonthemost distinguishableandshortest-latency
response, as it has been reported that P30 originates ipsilat-
erallytothestimulationattheclos epr o ximityoftheprimary
motor cortex (M1) [33].
2.4. Statistical Analyses. To test how well the P30 amplitude
would be able to discriminate the groups from each other,
receiver operating characteristic (ROC) curve analysis was
conducted. Area under the ROC curve (AUC)was computed
to determine how well the groups could be discriminated
based on the P30 amplitude. The asymptotic signiﬁcance for
the AUC was computed with the null hypothesis of AUC =
0.5. The optimal cut-oﬀ point for the ROC curve was deter-
mined as the closest point to the diagonal line connecting
points (0, 1) and (1, 0) in the ROC plot.
Diﬀerences in P30 amplitude between the groups were
analysed applying a mixed linear model, and using group
and hemisphere as ﬁxed variables and subject as a random
variable. Restricted maximum likelihood estimation was
used in the model. Mean eﬀects between the groups were
analysed using post-hoc analysis with least signiﬁcant dif-
ference adjustment (LSD).Also, individual mean amplitudes
for the P30 (hemispheric values averaged, P30mean)w e r e
used in the comparisons. Then, Mann-Whitney test was
applied in comparison of the diﬀerencesbetween the groups.
Correlations between the scores of dementia rating scales
and P30 amplitude were conducted using Spearman’s rank
correlation (ρ). The tests for correlation signiﬁcance were
two tailed. The correlated dementia scores were the global
score and sum of boxes score of the clinical dementia rating
scale (CDR-SOB) as well as MMSE. Statistical tests were
conducted using SPSS 17 (SPSS Inc., Chicago, IL). Level of
statistical signiﬁcance was set at P< . 05.
3.Results
The resting MTs (average of both hemispheres) for the
opponenspollicis muscleof the control, MCI, and ADgroup
were 44±11,48±12,and41±4%ofthemaximumstimulator
output,respectively. Nosigniﬁcant diﬀerenceswere observed
between the groups. The hemispheric data and data for
pooled samples were presented in our previous study [39],
where we found that the MT of the left hemisphere in MCI
subjects (50 ± 13% of the maximum stimulator output) was
signiﬁcantly higher (P<. 05) than in AD patients (42 ±
4% of the maximum stimulator output). Additionally, on
the right hemisphere, the MT of the controls (40 ± 11%
of the maximum stimulator output) was signiﬁcantly lower
(P<. 05) than in MCI subjects (48 ± 13% of the maximum
stimulator output).
Dementia scales for the subject groups were distinctive
of the diﬀerent disease conditions. MMSE for control, MCI,
and AD group was 27 ± 4, 25 ± 3, and 22 ± 5, respectively.
The global CDR values were 0 for controls, 0.5 for MCI
subjects, and 0.5 (n = 4) or 1.0 (n = 1) for AD patients.
Corresponding values for the CDR-SOB were 0.0 ± 0.0,
1.9 ± 1.1, and 3.2 ± 2.5, respectively. CDR and CDR-SOB
values in controls were signiﬁcantly lower (P<. 001) than
in MCI and AD subjects, while MMSE was nonsigniﬁcantly
higher (P = .055) in controls as compared to AD group.
Also,nosigniﬁcant diﬀerencewasobservedbetweencontrols
and MCI subjects in MMSE (P = .437).
The P30 peak was lower in amplitude in the AD patients
than in the controls (Figure 3, Table 1). No signiﬁcant4 International Journal of Alzheimer’s Disease
Table 1: Group-wise values of P30 amplitude.
P30 amplitude (μV)
Control MCI AD
Left hemisphere 32.0 ± 6.02 5 .6 ±12.71 7 .7 ±7.1
Right hemisphere 33.0 ± 14.61 6 .3 ±5.91 1 .5 ±4.9
P30mean 32.5 ± 9.82 1 .1 ±8.21 6 .0 ±6.9
∗
∗P<. 05 as compared to controls, linear mixed model (pooled values), and Mann-Whitney test (mean or hemisphericvalues).
Abbreviations:
MCI: Mild cognitive impairment
AD: Alzheimer’s disease
P30mean: P30 amplitude,mean of P30 amplitudes on both hemispheres.
100ms
10μV
31.4ms, 4.3μV
30ms, 8.7μV
30ms, 9.5μV
MCI
AD
Control
Figure 2: Grand average curves for TMS-evoked EEG responses as
measured from the central electrode (CZ). The mean peak for the
P30 has been indicated. However, P30 was analyzed for individuals
from the electrode chosenbased onthe shortestlatency andclearest
identiﬁcation on the stimulated hemisphere. The turquoise area
represents the95%conﬁdenceintervalforthe TMS-EEG responses.
The vertical black line indicates the momentof stimulation.
diﬀerence was observed between the controls and MCI
subjects (P = .054) or between the MCI and AD groups
(P = .336). No signiﬁcant diﬀerences were observed in the
latencies between the groups (data not shown). Also, no
signiﬁcantinterhemisphericdiﬀerencesinP30wereobserved
(P = .097).
The diﬀerent groups were discriminated from each other
by the ROC curve analysis (Figure 4). The AUC indicated
that the discrimination of controls from the MCI and
AD groups is possible based on TMS-induced P30 peak
amplitude (AUC = 0.900, P = .024, P30mean). The optimal
cut-oﬀ point was found to be 24.5μV (sensitivity of 0.75
and speciﬁcity of 0.80). Similarly, as the amplitude of the
P30 peak was lower in the AD group as in the other groups,
the ROC curve indicated that the discrimination of the AD
groupfromcontrolsandMCImaybepossible(AUC=0.882,
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Figure 3: Group-wise P30 amplitudes. The individual values are
presented as a mean value of P30 amplitude measured from both
hemispheres.Blacklinerepresents thegroup-wise meanvaluewhen
moving from controls to MCI and AD.
P = .053, P30mean). The optimal cut-oﬀ point in this case
was 20.2μV (sensitivity of 0.80 and speciﬁcity of 0.78).
If only the discrimination of AD patients from controls
was estimated, the AUC increased to 0.950 (P = .027,
P30mean). The optimal cut-oﬀ point was 25.4μV (sensitivity
of 0.80 and speciﬁcity of 0.75). Discrimination of MCI
from AD using ROC curve was found more diﬃcult (AUC
= 0.720, P = .251, P30mean). The optimal cut-oﬀ point
then was 18.7μV (sensitivity of 0.60 and speciﬁcity of
0.60). However, the more important discrimination of MCI
subjects from controls was found stronger although the AUC
was 0.850 (P = .086, P30mean). The optimal cut-oﬀ point
was25.5μV (sensitivity of0.75andspeciﬁcity of0.80),which
was very close to similar as in discriminating AD patients
from controls.
Signiﬁcant correlations were observed between the P30
amplitude and the dementia scales. An inverse correlation
was found between the global CDR and P30 amplitude as
well as between CDR-SOB and P30 amplitude (Figure 5).
As the global CDR is a classiﬁcation variable, its correla-
tions with P30 amplitude should be interpreted with care.International Journal of Alzheimer’s Disease 5
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Figure 4: Receiver operating characteristic (ROC) curves for distinguishing (a) controls from MCI and AD, and (b) and AD patients from
M C Ia n dc o n t r o ls u b j e c t sb a s e do nT M S - E E GP 3 0 .T u r q u o i s el i n ei n d i c a t e st h eR O Cc u r v ef o ra v e r a g e dd a t a ,w h i l et h eg r e ya n db l a c kl i n e s
indicate ROC curves for the right and left hemisphere, respectively. The area under the ROC curve (AUC) has been given separately for the
averaged (P30mean) and hemispheric data. The asymptotic signiﬁcance has been indicated with the null hypothesis of AUC = 0.5 (diagonal
line).
Table 2: Correlation coeﬃcients (Spearman’s ρ) between the P30 amplitude and dementia rating scales.
Mini-mental state examination Clinical dementia rating—global† Clinical dementia rating—sum of boxes
Left hemisphere 0.456 −0.678
∗∗ −0.788
∗∗∗
Right hemisphere 0.631
∗ −0.705
∗∗ −0.849
∗∗∗
P30mean 0.537
∗ −0.698
∗∗ −0.808
∗∗∗
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001.
†As the global CDR is a classiﬁcationvariable, its correlations withP30 amplitudeshould be interpreted with care.
Abbreviations:
P30mean: P30 amplitude,mean of P30 amplitudes on both hemispheres.
ApositivecorrelationwasfoundbetweentheMMSEandP30
amplitude (Table 2).
4.Discussion
We have previously shown that TMS-evoked P30 amplitude
is reduced in the AD subjects in the temporoparietal area,
ipsilateral to the stimulation side as well as in the contralat-
eral frontocentral cortex corresponding to the sensorimotor
area [39]. In the present study, we further investigated our
previously published data and found that the discrimination
of control subjects from MCI and AD subjects may be
possible with good sensitivity (Figures 3 and 4). Further,
consistently with our hypothesis, we found that there is a
signiﬁcant relation between the commonly used dementia
ratingscalesandtheanalyzedTMS-EEGresponseP30ampli-
tude, when TMS is focused on the M1 with suprathreshold
intensity (Figure 5). Our results suggest that the use of TMS-
EEG in the evaluation of AD and its initial signs could be
feasible as distinct changes occur in the measured responses
during the development of AD.
The greatest limitation of this study was that the group
sizes were small. In spite of that, the ﬁndings of the present
study showed clearly signiﬁcant diﬀerences between the
groups. In the future, these results should be further veriﬁed
by other studies with larger group sizes. Nevertheless, it was
clear that the discrimination of probable mild AD patients
and MCI subjects from control subjects seemed feasible.
Furthermore, the present study was able to show a correla-
tion between the P30 amplitude of the TMS-EEG and the
dementia rating scales (Figure 5, Table 2). Such relation has
not been reported earlier. Therefore, it seems that the P30
peak is indeed related to cognitive decline, or perhaps to the
developing motor deﬁcits that the AD patients may exhibit
in the advanced stage of the disease [11]. Due to the small
sample size, the study may suﬀer a lack of power to provide
reliable answers to its aim, that is, some of the intergroup
relations and diﬀerences may have been missed. Even with6 International Journal of Alzheimer’s Disease
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Figure 5: Scatter plot indicating the relation between the clinical
dementia rating sum of boxes and P30 amplitude (average of each
subject’s leftandrighthemispheremeasurement,P30mean).Thethin
curved linesrepresent the95%conﬁdenceintervalsforthecurve ﬁt.
the small sample size, the found eﬀect size for discriminating
controls from mild AD patients based on the P30mean was
large (Cohen’s d>0.8), as was the eﬀect size for the controls
and MCI diﬀerence (Cohen’s d>0.8). A medium size eﬀect
was observed between the MCI and AD (Cohen’s d>0.5).
However, the statistical signiﬁcance of those comparisons
was too weak in the last two cases. This encourages further
studies with larger sample sizes.
As opposed to the localized (single-channel) P30 re-
sponses reported in the present study, our previous study
investigated the global mean ﬁeld power (GMFP) of the
P30 peak [39]. Hence, for comparison, the global mean
ﬁeld power (GMFP) was computed for the P30 response
peaks (P30GMFP)[ 49]. We found that the P30GMFP correlated
strongly with the single-channel P30mean(ρ = 0.810, P<
.001). This correlation is aﬀected by the diﬀerences in the
P30 spread between the groups, and hence the correlation
may not be an ideal indicator for similar behavior. In the
discrimination of the diﬀerent groups, P30GMFP was weaker
than the single-channel P30mean, that is, in the ROC analysis,
controls were not discriminated as easily from the MCI and
AD (AUC = 0.775, P = .120) or the AD group from MCI
and control groups (AUC = 0.756, P = .125). Furthermore,
the P30GMFP exhibited some correlations with the dementia
scales (P30GMFP versus MMSE, ρ = 0.311,P = .279; P30GMFP
versus CDR, ρ =− 0.515, P = .060; P30GMFP versus CDR-
SOB, ρ =− 0.755, P = .002). Therefore, to us it seems that
the localized P30 amplitude is more sensitive in observing
cognitive decline as compared to global ﬁeld values. This
ﬁnding may be inﬂuenced by the modiﬁed spread of the P30
componentinAD,which wasobservedinourpreviousstudy,
and which aﬀects the GMFP [39].
The CDR is a standard assessment tool that yields global
and CDR-SOB scores. The global CDR score is often used to
stage dementia severity [45]. However, the CDR-SOB score
is a more detailed general index and is more sensitive in
assessing mild dementia [50–52]. Based on the CDR-SOB,
the AD patients in this study had very mild or mild dementia
[52]. In agreement with our hypothesis, we found signiﬁcant
correlations between the P30 amplitude and the dementia
scales (Table 2). As the CDR-SOB is a detailed and one of
the most used dementia scales, it also related best to the
P30 amplitude as was seen from their strong correlation
(Figure 5). Also, the other applied dementia scales correlated
with P30. Therefore, it seems that P30 indeed relates to the
severity of the AD even in a mild stage of the disease as the
patients were in the present study. Since our recent study
showed some eﬀect of cognitive decline on the N100 [39],
we analyzed the N100 response from the TMS-EEG at the
vertex for comparison with the P30 amplitude. We found
that none of the dementia scales correlated signiﬁcantly with
the N100 amplitude (N100 versus MMSE, ρ =− 0.029;
N100 versus CDR, ρ = 0.333; N100 versus CDR-SOB, ρ =
0.177). Therefore, P30 appears more speciﬁc than N100 in
identifying cognitive decline with TMS-EEG. The reason for
this may be that TMS-induced N100 response also includes
an auditory component, which does not aﬀect P30 [42].
Currently, the origin of P30 is not precisely described.
It has been suggested to originate from the ipsilateral
sensorimotor/premotor cortex border [41]o rt h ei p s i l a t e r a l
supplementary motor area [53]. As discussed by M¨ aki and
Ilmoniemi, the P30 may not reﬂect activation directly at
the location activated by the stimulus. However, it may still
reﬂect the degree of excitation in M1 [33]. Bonato et al.
showed that P30 vanishes if the activation of M1 is induced
with TMS coil oriented nonoptimally, which supports the
idea that P30 is descriptive of cortical activation related to
M1 excitation [40]. Considering the ﬁndings of the present
study, the decrease in P30 in AD as compared to healthy
controls may reﬂect impaired cortical activation in response
to M1 activation. However, if we considerthe earlier ﬁndings
relating MEPs with P30, the P30 measured in the present
study would not directly relate to motor activation, as the
earlier reports have indicated a positive correlation between
the two [33, 40]. In our earlier study [39], we showed that
thecorrelationbetweentheinducedMEPsandP30exhibitsa
nonsigniﬁcant negative trend when correlated over diﬀerent
patient groups (ρ =− 0.224, P = .441). When comparing
the mean values of MEP amplitudes, the controls exhibit
the lowest mean MEP amplitude of 1.0mV while showing
the highest P30 amplitude. Instead, the highest mean MEP
amplitude of 2.9mV was in the AD group with the lowest
P30 amplitude (Figure 3). This suggests that P30 is not only
related to the excitation of M1, but also other mechanisms
may inﬂuence it when AD progresses. Ferreri et al. [38]
suggested that P30 may be connected to GABAA receptors,
provided that P30 modulation is related to fast inhibitoryInternational Journal of Alzheimer’s Disease 7
postsynaptic potentials. Hence, considering the earlier ﬁnd-
ings suggesting reduction in GABAA -mediated SICI of
AD patients [3, 18–20], the reduction in P30 amplitude in
relation to cognitive decline could be explained by possibly
aﬀected GABAA activity in AD patients, even if the eﬀect is
not directly caused by the disease. However, based on the
presentstudy,we cannot revealthemechanism aﬀectingP30,
and future studies are required.
As the P30 has been suggested to relate to motor fun-
ction/control in response to TMS of the M1 [33, 40], it is
obvious that it may also be aﬀected by the motor function
impairment related to the developmentof AD. Furthermore,
as the connectivity of the AD patients is also impaired,
the subcortical contributor to the P30 may suﬀer leading
to a decrease in P30 amplitude (Figure 5). The indications
of P30 decrease are already present in the MCI subjects
(Figure 4) although they are insigniﬁcant (P = .054) in
the present study, likely due to the low number of subjects.
One possibility is that the P30 decline in AD is a result of
the missing connections or cortical atrophy, and the actual
function, which is still unclear, is related to the cortical
hyperexcitability [19, 54] or cholinergic dysfunction leading
to disinhibition [17–19, 55]. Hence, we will further study on
how the dementia symptoms relate to the connectivity and
the components of the TMS-EEG in our future studies with
larger material.
We cannot rule out the possible eﬀect of medication
in our ﬁndings, as the AD patients were on cholinesterase
inhibitors. However, in our previous study [39], we found
that the later part of the TMS-EEG response appeared partly
similar to that of the controls, meaning that not the entire
TMS-EEG response is inﬂuenced by either the AD or the
medication,orthatthecholinesteraseinhibitorsarecompen-
sating for some of the changes. The eﬀect of cholinesterase
inhibitors on the motor cortex excitability has been studied
earlier. Korchounov et al. [56] found that the MTs or SPs
were not aﬀected by the acetylcholinesterase inhibitor in
healthy subjects, while the intracortical inhibition and facili-
tationwere aﬀectedbetween 2 and 6 hours ofthe medication
intake.ThemotorcortexdisinhibitioninADhasbeenshown
to recover partly by the use of cholinesterase inhibitors [55].
Studying the eﬀect of cholinesterase inhibitors on the TMS-
EEG response of healthy subjects, possibly in combination
with paradigms such as SAI or paired-pulse TMS, could help
to understand the origin of P30.
5.Conclusions
We found diﬀerences in TMS-induced P30-component
amplitude between the controls and AD patients, indicating
impaired/altered connectivity in AD. In addition, we found
that the cognitive decline correlated with the P30 amplitude.
Further investigations with larger sample sizes are needed
to support our conclusion that TMS-EEG could be a
potentialnoninvasivebiomarkerforidentifyingMCIandAD
subjects and separating those from healthy population, and
for identifying connectivity changes occurring during the
development of AD.
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